Collaboration with a leading international animal health company to evaluate technology
Second collaboration within the past month
Biosignal Limited has signed an agreement with a leading animal health company to evaluate Biosignal's unique anti-microbial technology for the potential development of new products for food producing animals.
The evaluation will be conducted and fully funded by the animal health company. This project represents a substantial investment by the animal health company and will focus on efficacy and pharmacokinetics in several animal models.
Animal health, globally, is an $18 billion business. As in humans, bacterial biofilms cause extensive disease in animals. Biosignal's technology has the ability to disrupt such biofilms.
"Biosignal is applying its anti-microbial technology in five key areas; industrial, agricultural, consumer, therapeutics and medical devices," said Professor Peter Steinberg, CEO of Biosignal. "We have only recently moved to develop agricultural and animal health applications, and this collaboration is our second evaluation partnership in these fields in recent weeks. Both partnerships are with very substantial companies."
"This collaborative agreement is a positive early step in our strategy to establish a dedicated animal health presence. It is exclusive during the term of the evaluation within the field of food animal applications."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
